Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Content Type:

Latest Additions

July 2016
The appropriate use of Tiered virus panels when assessing HIV-1 vaccine-elicited neutralizing antibodies
June 2016
Development of SHIVs for Vaccine Evaluation in NHP
April 2016
Innovative Uses of Technology in HIV Clinical Trials
November 2015
Product Development Boot Camp
October 2015
Cent Gardes Conference: HIV Vaccines
September 2015
Germinal Center Dynamics and HIV Vaccines
July 2015
What's next for HIV Vaccines
June 2015
HIV Envelope Protein Manufacturing
May 2015
Design, Test, Repeat: Paths to Elicit Neutralizing Antibodies - A virtual Mini Symposium
May 2015
Nucleic Acid Delivery Devices for HIV Vaccines
September 2014
How complement stimulates B cell responses
November 2013
Therapeutic Vaccines
September 2013
Antibody Durability Think Tank
May 2013
Vaccine-Induced Sero-Positivity/Sero-Reactivity (VISP/SR)
Browse by: Sort by:
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 25 of 53
History and Definition of Tiers
How did Tier phenotyping come about and what is it?
David Montefiori
Duke University Medical Center
Defining Tiers
Bette Korber
Los Alamos National Laboratory
Tiered-ness: a structural biology point of view
Xiangpeng Kong
NYU School of Medicine
Timely Topic from The appropriate use of Tiered virus panels when assessing HIV-1 vaccine-elicited neutralizing antibodies on 7 July 2016 12:00 PM-1:30 PM
The Utility of Tier 1 Viruses
A case for discarding testing of neutralization of Tier 1 viruses
David Montefiori
Duke University Medical Center
Tier-1 panel: Not ideal, but useful
Shan Lu
Massachusetts Medical School
Heterologous Tier 1 R5 SHIV-C challenges: Correlates of protection
Ruth Ruprecht
Texas Biomedical Research Institute
Timely Topic from The appropriate use of Tiered virus panels when assessing HIV-1 vaccine-elicited neutralizing antibodies on 7 July 2016 1:30 PM-3:30 PM
Looking Forward
Lessons learned from vaccine specific Influenza-specific B cells
Adrian McDermott
Vaccine Research Center, NIAID, NIH
Virus panels for assessing vaccine-elicited neutralizing antibodies
Michael Seaman
BIDMC/Harvard Medical School
Utilizing real-time virus panels to characterize vaccine breadth, potency, and escape
Christos Petropolous
LabCorp
Timely Topic from The appropriate use of Tiered virus panels when assessing HIV-1 vaccine-elicited neutralizing antibodies on 7 July 2016 3:30 PM-6:00 PM
Development of SHIVs for Vaccine Evaluation in NHP
Introduction
Yegor Voronin
Global HIV Vaccine Enterprise
Workshop Overview
Alan Schultz
Division of AIDS, NIAID
Transmitted/Founder SHIVs
Theodora Hatziioannou
The Aaron Diamond AIDS Research Center
“Designer” SHIVs for HIV Vaccine and Cure Research
George M. Shaw
University of Pennsylvania
Discussion
Timely Topic from Development of SHIVs for Vaccine Evaluation in NHP on 6 June 2016 12:00 PM-1:00 PM
Welcome and Objectives
Welcome and Objectives
Yegor Voronin
Global HIV Vaccine Enterprise
Timely Topic from Innovative Uses of Technology in HIV Clinical Trials on 14 April 2016 8:30 AM-8:40 AM
Data Security and Responsible Data Use
Beyond IRB: Responsible Data in Clinical Trials
Alix Dunn
The Engine Room
Protecting participant confidentiality on mobile devices: managing risks to participant privacy in clinical studies that use mobile phones and data networks
Chris Whalen
RDCT
Timely Topic from Innovative Uses of Technology in HIV Clinical Trials on 14 April 2016 8:40 AM-9:40 AM
Uses of mHealth for Participant Communication, Intervention, and Monitoring in Clinical Trials
Engaging youth for health research and health promotion via Text and other Social Media: Challenges in a crowded and competitive environment
Sheana Bull
University of Colorado Denver
Electronic devices and SMS for adherence measurement and intervention in developing settings
Jessica Haberer
Harvard University
Use of cell phones to collect daily diary data in studies of sexual behaviors
Barbara Van Der Pol
University of Alabama Birmingham
Sexual and behavioral risk data collected via different platforms: phone-based surveys and in-clinic reporting in the HVTN 915 study
Janan Dietrich
Perinatal HIV Research Unit (PHRU)
Timely Topic from Innovative Uses of Technology in HIV Clinical Trials on 14 April 2016 9:45 AM-12:00 PM
eSource and Paperless Workflow
Paperless workflow in resource-constrained environments
Matt Johnston
MHRP
Tomorrow's Clinical Trials, Today
Megan McBride
Janssen Pharmaceutical Companies of Johnson & Johnson
Timely Topic from Innovative Uses of Technology in HIV Clinical Trials on 14 April 2016 12:45 PM-1:45 PM
Applications of Biometric Devices
The landscape of current biometric technology and use in global health and clinical trials
Peter Simpson
iRespond
Overview of IAVI Fingerprint projects, and use of fingerprinting in fishing communities in Uganda
Anatoli Kamali
Medical Research Council Uganda and IAVI
Use of electronic fingerprinting among female sex workers in Zambia
Kristin Wall
Emory University
Timely Topic from Innovative Uses of Technology in HIV Clinical Trials on 14 April 2016 1:45 PM-4:35 PM
Wrap up
Closing Remarks
Yegor Voronin
Global HIV Vaccine Enterprise
Timely Topic from Innovative Uses of Technology in HIV Clinical Trials on 14 April 2016 4:35 PM-4:45 PM
Video summaries of modules
BootCamp Overview
Yegor Voronin
Global HIV Vaccine Enterprise
Module 1 Summary: Pipeline and Portfolio Considerations
Sanjay Phogat
Sanofi Pasteur
Jerry Sadoff
Janssen Pharmaceutical Companies
Penny Heaton
The Bill & Melinda Gates Foundation
Mary Marovich
National Institutes of Health (NIAID)
Carlos Diaz Granados
Sanofi Pasteur
Robin Shattock
Imperial College London
Module 2 Summary: Target Product Profile
Jane Halpern
Division of AIDS, NIAID, National Institutes of Health
Jerry Sadoff
Janssen Pharmaceutical Companies
Charla Andrews
TRI
Carlos Diaz Granados
Sanofi Pasteur
Jim Ackland
Global Biosolutions
Michael Seggev
SeggevM Consulting
Module 3 Summary: From Bench to Clinic
Michael Pensiero
Division of AIDS, NIAID, National Institutes of Health
Jim Ackland
Global Biosolutions
Robin Shattock
Imperial College London
Dan Barouch
Harvard University
Timothy Cardozo
New York University
Nina Russell
The Bill & Melinda Gates Foundation
Jerry Sadoff
Janssen Pharmaceutical Companies
Tom Hassell
International AIDS Vaccine Initiative
Timothy Fouts
Profectus BioSciences
Module 4 Summary: Planning for Trial Success
Anne Mullin
Shift Health
Nina Russell
The Bill & Melinda Gates Foundation
Ryan Wiley
Shift Health
Jerry Sadoff
Janssen Pharmaceutical Companies
Module 5 Summary: Product Development Partnerships
Ryan Wiley
Shift Health
Robert O'Connell
USMC, AFRIMS
Jerry Sadoff
Janssen Pharmaceutical Companies
Timothy Cardozo
New York University
Thomas Denny
Duke Medical Center
Nina Russell
The Bill & Melinda Gates Foundation
Robin Shattock
Imperial College London
James Kublin
HIV Vaccine Trials Network
Timely Topic from Product Development Boot Camp on 6 November 2015 3:30 PM-5:00 PM
Introduction
Welcome and Opening Remarks
Bill Snow
Global HIV Vaccine Enterprise
Welcome and Opening Remarks
Ryan Wiley
Shift Health
Timely Topic from Product Development Boot Camp on 5 November 2015 8:30 AM-8:50 AM
Pipeline and Portfolio Considerations – Module 1
Principles of portfolio management in industry
Jerry Sadoff
Janssen Pharmaceutical Companies
Principles of portfolio management in foundations
Penny Heaton
The Bill & Melinda Gates Foundation
Principles of portfolio management in governments
Mary Marovich
National Institutes of Health (NIAID)
Integrated approaches to portfolio management
Carlos DiazGranados
Sanofi Pasteur
Moderator
Sanjay Phogat
Sanofi Pasteur
Panel Discussion
Jerry Sadoff
Janssen Pharmaceutical Companies
Panel Discussion
Penny Heaton
The Bill & Melinda Gates Foundation
Panel Discussion
Mary Marovich
National Institutes of Health (NIAID)
Panel Discussion
Carlos DiazGranados
Sanofi Pasteur
Outcomes of the "Visualizing Immune Landscape" Timely Topic
Yegor Voronin
Global HIV Vaccine Enterprise
Timely Topic from Product Development Boot Camp on 5 November 2015 10:30 AM-11:10 AM
Target Product Profile (TPP) – Module 2
Overview of TPP: why and how to create a TPP
Jane Halpern
Division of AIDS, NIAID, National Institutes of Health
Moderator
Sanjay Phogat
Sanofi Pasteur
Panel Discussion
Jane Halpern
Division of AIDS, NIAID, National Institutes of Health
Panel Discussion
Carlos DiazGranados
Sanofi Pasteur
Panel Discussion
Tom Hassell
International AIDS Vaccine Initiative
Panel Discussion
Jerry Sadoff
Janssen Pharmaceutical Companies
Timely Topic from Product Development Boot Camp on 5 November 2015 11:45 AM-12:15 PM
Moving Vaccine Candidates from Bench to Clinic – Module 3
Phase and goal-appropriate product development
Michael Pensiero
Division of AIDS, NIAID, National Institutes of Health
Preclinical data and regulatory considerations
Jim Ackland
Global Biosolutions
Compare and contrast case studies: Research- and product-oriented development
Robin Shattock
Imperial College London
Compare and contrast case studies: Research- and product-oriented development
Dan Barouch
Harvard University
Moderator
Tom Hassell
International AIDS Vaccine Initiative
Moderator
Michael Pensiero
Division of AIDS, NIAID, National Institutes of Health
Panel Discussion
Jim Ackland
Global Biosolutions
Panel Discussion
Michael Pensiero
Division of AIDS, NIAID, National Institutes of Health
Panel Discussion
Robin Shattock
Imperial College London
Panel Discussion
Dan Barouch
Harvard University
Timely Topic from Product Development Boot Camp on 5 November 2015 4:00 PM-5:00 PM
Planning for Trial Success – Module 4
Recap of Day 1 and Introduction to Day 2
Ryan Wiley
Shift Health
Concept overview of planning for success
Anne Mullin
Shift Health
Dengue vaccine late stage development
Sanjay Phogat
Sanofi Pasteur
P5 development plans
Nina Russell
The Bill & Melinda Gates Foundation
Moderator
Tom Hassell
International AIDS Vaccine Initiative
Panel Discussion
Anne Mullin
Shift Health
Panel Discussion
Carlos DiazGranados
Sanofi Pasteur
Panel Discussion
Nina Russell
The Bill & Melinda Gates Foundation
Panel Discussion
James Kublin
HIV Vaccine Trials Network
Panel Discussion
Jerry Sadoff
Janssen Pharmaceutical Companies
Timely Topic from Product Development Boot Camp on 6 November 2015 10:20 AM-11:20 AM
Product Development Partnerships: Best Practices – Module 5
Formation and Governance, Tech transfer and IP considerations
Ryan Wiley
Shift Health
Contrast and compare the different approaches of Janssen and P5
Robert O'Connell
USMC, AFRIMS
Contrast and compare the different approaches of Janssen and P5
Jerry Sadoff
Janssen Pharmaceutical Companies
Moderator
Ryan Wiley
Shift Health
Moderator
Nina Russell
The Bill & Melinda Gates Foundation
Panel Discussion
Robert O'Connell
USMC, AFRIMS
Panel Discussion
Tom Denny
Center for HIV/AIDS Vaccine Immunology, Duke University
Panel Discussion
Jerry Sadoff
Janssen Pharmaceutical Companies
Panel Discussion
James Kublin
HIV Vaccine Trials Network
Timely Topic from Product Development Boot Camp on 6 November 2015 1:00 PM-2:00 PM
Wrap-up Session
Panel Discussion
Yegor Voronin
Global HIV Vaccine Enterprise
Panel Discussion
Ryan Wiley
Shift Health
Panel Discussion
Tom Hassell
International AIDS Vaccine Initiative
Closing Remarks
Bill Snow
Global HIV Vaccine Enterprise
Timely Topic from Product Development Boot Camp on 6 November 2015 3:00 PM-3:15 PM
Introduction
Welcome address
Benoît Miribel
Fondation Mérieux, France
Welcome address
Jean-François Delfraissy
Agence Nationale de Recherche sur le Sida (ANRS), France
Welcome address
Marc Girard
Académie Nationale de Médecine, France
The T cell pathway
Bruce Walker
Ragon Institute of MGH, MIT and Harvard, United States
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 25 October 2015 2:00 PM-4:00 PM
Blocking Virus Entry
Impact of HIV phenotype on transmission and disease progression
Eric Hunter
Emory University, United States
Type I Interferons: Barriers or Pathways to Virus Entry?
Netanya Sandler-Utay
University of Texas Medical Branch at Galveston, United States
An approach to long-lived protection from HIV-1
Michael Farzan
The Scripps Research Institute, United States
Inactivated AT-2 treated SIVmac239 and Lactobacillus plantarum (LP) as a candidate AIDS vaccine
Guido Silvestri
Emory University, United States
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 25 October 2015 4:45 PM-7:45 PM
Broadly Neutralizing Antibodies
Broadly neutralizing antibodies to HIV
Dennis Burton
The Scripps Research Institute, United States
Reproducible antibody lineages as templates for vaccine design
Peter Kwong
National Institute of Allergy and Infectious Diseases, United States
Broadly neutralizing antibody 8ANC195 recognizes closed and open conformational states of HIV-1 Env
Pamela Bjorkman
California Institute of Technology, United States
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 26 October 2015 8:00 AM-10:00 AM
Passive Immunization and VIP
Overview of HIV Antibodies for Prevention and Treatment
John Mascola
Vaccine Research Center, NIAID, NIH, United States
Passive Immunization for Prevention and Treatment of HIV
Barney Graham
Vaccine Research Center, NIAID, NIH, United States
Ability to Develop Broadly Neutralizing HIV-1 Antibodies is not Restricted by the Germline Immunoglobulin Gene Repertoire
Lynn Morris
National Institute for Communicable Diseases, South Africa
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 26 October 2015 10:45 AM-1:00 PM
Antibody Effector Functions
Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control
Margie Ackerman
Dartmouth College Thayer School of Engineering, United States
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 26 October 2015 2:00 PM-4:00 PM
Mucosal Immune Responses
Prevention of HIV Infection at Mucosal Sites of HIV Exposure
Julie McElrath
Fred Hutchinson Cancer Research Center, United States
Characterizing antibodies from new populations
Julie Overbaugh
Fred Hutchinson Cancer Research Center, United States
Natural control of HIV-1 infection in the uterine mucosa: a model for developing novel protective vaccine strategies?
Elizabeth Menu
Center for immunology of viral infections and autoimmune diseases, France
The in vivo effects of anti- a4b7 in rhesus macaques during acute and chronic infection
James Arthos
National Institute of Allergy and Infectious Diseases, United States
Genital mucosal inflammation and HIV prevention: barriers to protection
Jo-Ann Passmore
University of Cape Town, South Africa
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 26 October 2015 4:45 PM-8:00 PM
Cellular Immune Responses
Cytomegalovirus Vectors: Exceptional Efficacy from Unconventional Cellular Immune Responses
Louis Picker
Oregon Health & Science University/Vaccine and Gene Therapy Institute, United States
eAccess Meeting from Cent Gardes Conference: HIV Vaccines on 27 October 2015 8:00 AM-10:25 AM
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 25 of 53